RU2005127808A - Применение генов семейства sgk для диагностики и терапии катаракты и глаукомы - Google Patents
Применение генов семейства sgk для диагностики и терапии катаракты и глаукомы Download PDFInfo
- Publication number
- RU2005127808A RU2005127808A RU2005127808/15A RU2005127808A RU2005127808A RU 2005127808 A RU2005127808 A RU 2005127808A RU 2005127808/15 A RU2005127808/15 A RU 2005127808/15A RU 2005127808 A RU2005127808 A RU 2005127808A RU 2005127808 A RU2005127808 A RU 2005127808A
- Authority
- RU
- Russia
- Prior art keywords
- hsgkl
- hsgk3
- gene
- cell groups
- hsgk1
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims 26
- 208000002177 Cataract Diseases 0.000 title claims 8
- 238000002560 therapeutic procedure Methods 0.000 title claims 2
- 210000004027 cell Anatomy 0.000 claims 17
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims 8
- 108091052347 Glucose transporter family Proteins 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 7
- 208000010412 Glaucoma Diseases 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- 238000012360 testing method Methods 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 239000000758 substrate Substances 0.000 claims 6
- 102100035493 E3 ubiquitin-protein ligase NEDD4-like Human genes 0.000 claims 5
- 101710155393 E3 ubiquitin-protein ligase NEDD4-like Proteins 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000026731 phosphorylation Effects 0.000 claims 3
- 238000006366 phosphorylation reaction Methods 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000006225 natural substrate Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 101100393884 Drosophila melanogaster Glut1 gene Proteins 0.000 claims 1
- 101710165986 Negative regulator of transcription Proteins 0.000 claims 1
- 101150058068 SLC2A1 gene Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000004186 co-expression Effects 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 238000011161 development Methods 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000054765 polymorphisms of proteins Human genes 0.000 claims 1
- 229940076372 protein antagonist Drugs 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/166—Cataract
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/168—Glaucoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10305212A DE10305212A1 (de) | 2003-02-07 | 2003-02-07 | Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom |
| DE10305212.7 | 2003-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005127808A true RU2005127808A (ru) | 2006-05-27 |
Family
ID=32730900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005127808/15A RU2005127808A (ru) | 2003-02-07 | 2004-02-05 | Применение генов семейства sgk для диагностики и терапии катаракты и глаукомы |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1663246A2 (enExample) |
| JP (1) | JP2006519189A (enExample) |
| KR (1) | KR20050114214A (enExample) |
| CN (1) | CN1771039A (enExample) |
| AU (1) | AU2004210416A1 (enExample) |
| BR (1) | BRPI0407300A (enExample) |
| CA (1) | CA2514703A1 (enExample) |
| DE (1) | DE10305212A1 (enExample) |
| MX (1) | MXPA05008394A (enExample) |
| PL (1) | PL378399A1 (enExample) |
| RU (1) | RU2005127808A (enExample) |
| WO (1) | WO2004069258A2 (enExample) |
| ZA (1) | ZA200506280B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1964705A (zh) * | 2004-03-11 | 2007-05-16 | 默克专利有限公司 | 干扰纤维化的方法 |
| RU2006135654A (ru) * | 2004-03-11 | 2008-09-10 | Мерк Патент ГмбХ (DE) | Способы модуляции глутаматных рецепторов для лечения нейропсихиатрических расстройств, включающие применение модуляторов сывороточных и индуцируемых глюкокортикоидами киназ |
| DE102004059781A1 (de) * | 2004-12-10 | 2006-06-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung der Serum-/Glucocorticoid regulierten Kinase |
| WO2007002670A2 (en) * | 2005-06-28 | 2007-01-04 | Bausch & Lomb Incorporated | Method of lowering intraocular pressure |
| JPWO2007037560A1 (ja) * | 2005-09-30 | 2009-04-16 | リンク・ジェノミクス株式会社 | Ｓｇｋ２遺伝子の治療的又は診断的用途 |
| JP5249774B2 (ja) * | 2005-11-22 | 2013-07-31 | マギル ユニバーシティ | 眼内圧調節初期遺伝子およびその使用 |
| WO2008079980A1 (en) * | 2006-12-22 | 2008-07-03 | Alcon Research, Ltd. | Inhibitors of protein kinase c-delta for the treatment of glaucoma |
| DE102008029072A1 (de) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen |
| BR112013018374A2 (pt) * | 2011-01-25 | 2016-10-11 | Monell Chemical Senses Centre | composições e métodos para fornecer ou modular o sabor doce e métodos para rastrear os mesmos |
| KR102357260B1 (ko) * | 2020-12-10 | 2022-02-08 | 주식회사 레피겐엠디 | 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트 |
| CN119303113A (zh) * | 2024-09-03 | 2025-01-14 | 河北大学附属医院 | Nedd4l基因在制备治疗血管内皮细胞增生性相关疾病药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996006863A1 (en) * | 1994-08-30 | 1996-03-07 | University Of Dundee | Agents for inducing apoptosis and applications of said agents in therapy |
| AU6263996A (en) * | 1995-06-07 | 1996-12-30 | Ligand Pharmaceuticals Incorporated | Method for screening for receptor agonists and antagonists |
| US5925523A (en) * | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| DE19708173A1 (de) * | 1997-02-28 | 1998-09-03 | Dade Behring Marburg Gmbh | Zellvolumenregulierte humane Kinase h-sgk |
| WO1999059559A1 (en) * | 1998-05-15 | 1999-11-25 | Joslin Diabetes Center | Independent regulation of basal and insulin-stimulated glucose transport |
| DE69937159T2 (de) * | 1998-12-14 | 2008-06-26 | University Of Dundee, Dundee | Verfahren zur Aktivierung von SGK durch Phosphorylierung. |
| US6399655B1 (en) * | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
| DE19917990A1 (de) * | 1999-04-20 | 2000-11-02 | Florian Lang | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
| WO2001004145A2 (en) * | 1999-07-14 | 2001-01-18 | University Of Lausanne | Glutx polypeptide family and nucleic acids encoding same |
| US6416759B1 (en) * | 1999-09-30 | 2002-07-09 | The Regents Of The University Of California | Antiproliferative Sgk reagents and methods |
| US20030236246A1 (en) * | 2002-04-30 | 2003-12-25 | Brazzell Romulus Kimbro | Method for decreasing capillary permeability in the retina |
| DE10225844A1 (de) * | 2002-06-04 | 2003-12-18 | Lang Florian | sgk und nedd als diagnostische und therapeutische targets |
-
2003
- 2003-02-07 DE DE10305212A patent/DE10305212A1/de not_active Withdrawn
-
2004
- 2004-02-05 AU AU2004210416A patent/AU2004210416A1/en not_active Abandoned
- 2004-02-05 WO PCT/EP2004/001048 patent/WO2004069258A2/de not_active Ceased
- 2004-02-05 PL PL378399A patent/PL378399A1/pl not_active Application Discontinuation
- 2004-02-05 CN CNA2004800070348A patent/CN1771039A/zh active Pending
- 2004-02-05 MX MXPA05008394A patent/MXPA05008394A/es unknown
- 2004-02-05 KR KR1020057014582A patent/KR20050114214A/ko not_active Withdrawn
- 2004-02-05 EP EP04708350A patent/EP1663246A2/de not_active Withdrawn
- 2004-02-05 JP JP2006501737A patent/JP2006519189A/ja active Pending
- 2004-02-05 BR BR0407300-2A patent/BRPI0407300A/pt not_active IP Right Cessation
- 2004-02-05 RU RU2005127808/15A patent/RU2005127808A/ru not_active Application Discontinuation
- 2004-02-05 CA CA002514703A patent/CA2514703A1/en not_active Abandoned
-
2005
- 2005-08-05 ZA ZA200506280A patent/ZA200506280B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1771039A (zh) | 2006-05-10 |
| BRPI0407300A (pt) | 2006-02-07 |
| AU2004210416A1 (en) | 2004-08-19 |
| PL378399A1 (pl) | 2006-04-03 |
| EP1663246A2 (de) | 2006-06-07 |
| CA2514703A1 (en) | 2004-08-19 |
| JP2006519189A (ja) | 2006-08-24 |
| DE10305212A1 (de) | 2004-08-19 |
| WO2004069258A2 (de) | 2004-08-19 |
| KR20050114214A (ko) | 2005-12-05 |
| MXPA05008394A (es) | 2005-10-05 |
| WO2004069258A3 (de) | 2005-02-24 |
| ZA200506280B (en) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ebermann et al. | PDZD7 is a modifier of retinal disease and a contributor to digenic Usher syndrome | |
| JP6448149B2 (ja) | 肝線維症に関連する遺伝的多型、その検出方法および使用 | |
| Schweisguth et al. | Antagonistic activities of Suppressor of Hairless and Hairless control alternative cell fates in the Drosophila adult epidermis | |
| El-Sayed et al. | Mutations in the beta propeller WDR72 cause autosomal-recessive hypomaturation amelogenesis imperfecta | |
| CA2100472C (en) | Inherited and somatic mutations of apc gene in colerectal cancer of humans | |
| JP2018057395A (ja) | 心筋梗塞に関連する遺伝的多型、その検出方法および使用 | |
| DE69734986T2 (de) | Mutationen innerhalb der diabetes-suszeptibilitätsgene für die hepatozyten kernfaktoren (hnf) hnf-1alpha, hnf-1beta und hnf-4alpha | |
| JP2003514538A (ja) | 哺乳動物毒物学的反応マーカー | |
| DE60109430T2 (de) | An entzündlichen darmerkrankungen beteiligte gene und deren verwendung | |
| RU2005127808A (ru) | Применение генов семейства sgk для диагностики и терапии катаракты и глаукомы | |
| JPH06500688A (ja) | 神経線維腫遺伝子 | |
| US8975018B2 (en) | Method of detecting expanded CAG repeat region in spinocerebellar ataxia-2 gene | |
| US11473143B2 (en) | Gene and mutations thereof associated with seizure and movement disorders | |
| KR102058624B1 (ko) | 감각신경성 난청 진단을 위한 마커 tmem43 및 그의 용도 | |
| JP2006519189A5 (enExample) | ||
| Katsanis et al. | Isolation of a paralog of the Doyne honeycomb retinal dystrophy gene from the multiple retinopathy critical region on 11q13 | |
| AU2007201232A1 (en) | Method for detecting growth hormone variations in humans, the variations and their uses | |
| US20050130171A1 (en) | Genes expressed in Alzheimer's disease | |
| US6844431B1 (en) | Nucleic acid encoding spinocerebellar ataxia-2 and products related thereto | |
| US20060141462A1 (en) | Human type II diabetes gene-slit-3 located on chromosome 5q35 | |
| DE60015559T2 (de) | Sentrin-spezifische menschliche protease senp1 | |
| WO2002053729A1 (fr) | Proteines bhlh, leurs genes et leurs utilisations | |
| Chen et al. | Characterization of the mouse gene, human promoter and human cDNA of TSCOT reveals strong interspecies homology | |
| Teng et al. | LncRNAs in the Dlk1-Dio3 Domain Are Essential for Mid-Embryonic Heart Development | |
| Kranc et al. | Association between GGA1 gene polymorphisms and occurrence of mammary mixed tumors and aging in domestic bitches1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080508 |